RE: This is the end.15 Jun 2021 09:51
Same to you, terrible end and totally unnecessary. I go back even further, when questions were raised in the p3 trials over liver toxicity prior to mtfb, why oh why was that not the first port of call to address, especially considering the trials were designed with the FDA.
It's a shame, in world where there has been chronic underinvestment in new antibiotics, and waining effectiveness of many of the current class, iclaprim would have been a useful addition. For whom? We don't actually know.
All the best for current and future Investments